Increased diagnostic accuracy and wider availability of high-end ocular imaging are significant drivers to the uveal melanoma treatment market. High-resolution optical coherence tomography, multimodal ...
83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage 57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increased ...
Servier, an independent international pharmaceutical group governed by a foundation, and IDEAYA Biosciences, Inc., a leading precision medicine oncology company, announced an exclusive license ...
ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better ...
The global uveal melanoma treatment market is poised for substantial growth, projected to reach a market valuation of USD 2.4 billion by 2033, up from USD 1.4 billion in 2023, reflecting a healthy ...
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 December 2024) The European Organisation for Research and Treatment of Cancer (EORTC), an independent clinical cancer research ...
Please provide your email address to receive an email when new articles are posted on . Brachytherapy was the most common treatment for patients with uveal melanoma. Patients with Medicaid or no ...
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy. 3d illustration of a T cell attacking a cancer cell ...
New research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback